BCLI Share Price | Brainstorm Cell Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Brainstorm Cell Therapeutics, Inc.?

Market Cap: As of Jun 18, Brainstorm Cell Therapeutics, Inc. has a market capitalization of 9.48 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.00 million and a net profit of -11.08 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -7.76 million, while total assets were reported at 1.83 million.

Q: What does Brainstorm Cell Therapeutics, Inc. do?

Overview: Brainstorm Cell Therapeutics, Inc. is a biotechnology company engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease (PD), among others, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Mar 2025) Market Cap: USD 9.48 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.00 Return on Equity: 155.00% Price to Book: -1.27Contact Details: Address: 1325 Avenue of the Americas Fl 28, NEW YORK NY: 10019-6583 Tel: 1 201 4880460 Fax: 1 302 6555049 Website: http://www.brainstorm-cell.com/

Q: Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Brainstorm Cell Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include bearish signals from the daily moving averages, Bollinger Bands, and KST, along with a mildly bearish reading from the Dow Theory on a weekly basis. The MACD shows mildly bullish signals on both weekly and monthly time frames, but this is overshadowed by the overall bearish trend. There is no return data available for comparison with the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.55 k

Shareholding (Sep 2025)

FII

0.23%

Held by 6 FIIs

DII

97.86%

Held by 2 DIIs

Promoter

0.00%

How big is Brainstorm Cell Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Brainstorm Cell Therapeutics, Inc. has a market capitalization of 9.48 million, with net sales of 0.00 million and a net profit of -11.08 million over the last four quarters. The company's shareholder's funds are -7.76 million, and total assets are 1.83 million.

View full answer

What does Brainstorm Cell Therapeutics, Inc. do?

22-Jun-2025

Brainstorm Cell Therapeutics, Inc. is a biotechnology company focused on developing adult stem cell therapies for neurodegenerative disorders like ALS, MS, and Parkinson's disease. It has a market cap of $9.48 million and reported a net profit loss of $3 million as of March 2025.

View full answer

Who are in the management team of Brainstorm Cell Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Brainstorm Cell Therapeutics, Inc. includes Prof. Jacob Frenkel (Chairman), Dr. Irit Arbel (Vice Chairman), Mr. Uri Yablonka (Executive VP, Chief Business Officer), and several independent directors. They oversee the company's strategic direction and operations.

View full answer

Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Brainstorm Cell Therapeutics, Inc. is in a bearish trend with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mildly bullish MACD signals on longer time frames.

View full answer

Compare Brainstorm Cell Therapeutics, Inc. with Similar Stocks

Cadrenal Therapeutics, Inc.BioCardia, Inc.Athersys, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.05

Return on Equity

150.24%

Price to Book

-0.85

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-12.58%

6 Months

-15.43%

1 Year

-68.29%

2 Years

-90.03%

3 Years

-78.39%

4 Years

-98.75%

5 Years

-99.51%

Brainstorm Cell Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

9.70%

EBIT to Interest (avg)

-15.90

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

11.57%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-1.30

EV to EBIT

-0.79

EV to EBITDA

-0.80

EV to Capital Employed

-1.30

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Sideways

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.9%)

Foreign Institutions

Held by 6 Foreign Institutions (0.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 22.22% vs -125.00% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.00",
          "val2": "-3.00",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.70",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 32.56% vs 29.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.50",
          "val2": "-21.20",
          "chgp": "45.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "4.70",
          "chgp": "-97.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.60",
          "val2": "-17.20",
          "chgp": "32.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.00

-3.00

33.33%

Interest

0.10

0.00

Exceptional Items

0.00

0.40

-100.00%

Consolidate Net Profit

-2.10

-2.70

22.22%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 22.22% vs -125.00% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.50

-21.20

45.75%

Interest

0.10

0.00

Exceptional Items

0.10

4.70

-97.87%

Consolidate Net Profit

-11.60

-17.20

32.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 32.56% vs 29.22% in Dec 2023

All Annual Results

Company CV

About Brainstorm Cell Therapeutics, Inc.

Brainstorm Cell Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Company Coordinates

Company Details

1325 Avenue of the Americas Fl 28 , NEW YORK NY : 10019-6583

Tel: 1 201 4880460

http://www.brainstorm-cell.com/

Registrar Details

Brainstorm Cell Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Brainstorm Cell Therapeutics, Inc.?

Watch in Real-Time

What does Brainstorm Cell Therapeutics, Inc. do?

Who are in the management team of Brainstorm Cell Therapeutics, Inc.?

Is Brainstorm Cell Therapeutics, Inc. technically bullish or bearish?

Compare Brainstorm Cell Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Brainstorm Cell Therapeutics, Inc.

Company Coordinates